Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma

Key facts

Sponsor

University of Colorado, Denver

Principal Investigator

Thomas W Flaig, MD

University of Colorado, Denver

Intervention

Erlotinib hydrochloride(drug)

Enrollment

25 enrolled

Eligibility

18 years · All sexes

Timeline

2006 – 2012

Study locations (1)

• University of Colorado Hospital, Aurora, Colorado, United States

Collaborators

Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for MITF-related melanoma and renal cell carcinoma predisposition syndrome

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT06307431
  A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE3NCT05078047
  Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
  UNICANCER
• ACTIVE NOT RECRUITINGPHASE1NCT04707248
  A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
  Daiichi Sankyo
• RECRUITINGNCT05785052
  Biomarkers of Renal Cancer
  Biorek S.R.L.
• ACTIVE NOT RECRUITINGPHASE1NCT03170960
  Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
  Exelixis
• RECRUITINGNCT00001238
  Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
  National Cancer Institute (NCI)

See all trials for MITF-related melanoma and renal cell carcinoma predisposition syndrome →